In February 2021, Creoptix, a subsidiary of Malvern Panalytical, launched WaveRAPID, a new and faster way of measuring kinetics to accelerate drug discovery

Northbrook, IL 60062 -- (SBWire) -- 01/16/2024 --Label-free Detection Market by Product & Service (Instruments, Consumables(Biosensor Chips, Microplates), Software), Technology(Surface Plasmon Resonance), Application (Hit Confirmation, Lead Generation), End User (Pharma, CROs) – Global Forecast to 2028" global label-free detection market is projected to reach USD 863 million by 2028 from USD 570 million in 2023, at a CAGR of 8.7% during the forecast period of 2023 to 2028. The growth of this market is driven by rising prevalence of target diseases and disorders, the availability of funding for life science research and development, effectiveness of label-free technology in drug discovery. Additionally, the technological advancement in label-free detection leading to expanded applications and adoption of label-free detection products.

In the near future, the label-free detection industry is poised to witness a revolutionary transformation, driven by advancements in cutting-edge technologies and increasing demand for non-invasive and real-time analysis in various sectors. Leveraging techniques such as surface plasmon resonance (SPR), interferometry, and optical biosensors, label-free detection systems will enable accurate and sensitive measurements without the need for chemical labels or complex sample preparation, making them faster, cost-effective, and environmentally friendly. This industry's growth will be propelled by applications spanning medical diagnostics, drug discovery, food safety, environmental monitoring, and more, offering researchers and industries unprecedented insights into molecular interactions and cellular behavior. As the technology matures, the label-free detection industry will undoubtedly revolutionize how we understand and analyze complex biological and chemical systems, paving the way for groundbreaking discoveries and transformative solutions to global challenges.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32435593

Browse in-depth TOC on "Label-free Detection Market"

193 - Tables
43 - Figures
252 – Pages

Key Market Players:

Key players in the label-free detection market include Danaher (US), Sartorius AG (Germany), Waters Corporation (US), PerkinElmer, Inc. (US), AMETEK, Inc. (US), HORIBA, Ltd. (Japan), Spectris (UK), METTLER TOLEDO International Inc., (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Hitachi High-Tech Corporation (Japan), Attana AB (Sweden), Bruker (US), NanoTemper Technologies GmbH (Germany), Affinité Instruments (Canada), Biosensing Instrument (US), Unchained Labs (US), BioNavis Ltd. (Finland), Carterra, Inc. (US), Nicoya (Canada), BiOptix Analytical LLC (US), Plexera Bioscience (US), XanTec Bioanalytics GmbH (Germany), lino Biotech AG (Switzerland), and KEP Technologies (France).

Label-free Detection Market Dynamics:

Drivers:

1. Introduction of technologically advanced products
2. Growing number of drug discovery programs through academic-industrial partnerships
3. High sensitivity of label-free technologies

Restraints:

1. High cost of instruments

Opportunities:

1. Growing life science research activities in emerging markets

Challenges:

1. Shortage of skilled professionals

Trends:

1. Rising pharmaceutical outsourcing
2. Impact of the COVID-19 outbreak on the label-free detection market

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=32435593

The instrument segment accounted for the largest share, by product & service in the label-free detection market in 2022.

By type, the label-free detection market has been further categorized as instruments, consumables, and software & services. The instrument segment held the largest share of the global label-free detection market in 2022. This can be attributed to Increasing R&D and the growing launches of label-free detection instruments. Label-free detection instruments are widely adopted by drug discovery researchers for applications such as kinetic studies, lead optimization, and pathway analysis. The use of labels in traditional drug discovery has been shown to cause undesirable and unanticipated interactions. Additionally, labeled technologies typically require the use of genetically modified cell lines, which can alter cellular behavior and can lead to false conclusions. These advantages are overcome by adoption of label free technologies.

The surface plasmon resonance segment accounted for the largest share of the technology segment in the label-free detection market in 2022.

Based on technology, the global label-free detection market has been segmented into surface plasmon resonance, differential scanning calorimetry, bio-layer interferometry, isothermal titration calorimetry, and other label-free detection technologies. The surface plasmon resonance segment held the largest market share in 2022. The large share of this segment can be attributed to high sensitivity of this technology and its wide usage in determining specificity, affinity, and kinetic parameters during the binding of macromolecules.

The North America region catered the largest share of the label-free detection market in 2022.

The label-free detection market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in label-free technologies, and collaborative initiatives contribute to the growth of the label-free detection market in the North America region. Additionally, rising research activity, increasing support for research from the public and private sectors, and growing pharma R&D spending are major drivers of the North American market.

Recent Developments:

- In April 2022, Sartorius launched the new Octet SF3, the first SPR system under the Sartorius Octet brand. Octet SF3 is a next-generation SPR instrument that offers robust, high-throughput, low maintenance characterization of biomolecular interactions.
- In February 2021, Creoptix, a subsidiary of Malvern Panalytical, launched WaveRAPID, a new and faster way of measuring kinetics to accelerate drug discovery.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=32435593

About MarketsandMarkets
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.